Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. possesses a favorable outlook due to the increasing interest in metabolic dysfunction-associated steatohepatitis (MASH) highlighted by Novo's acquisition of Akero Therapeutics, suggesting a strong market potential for innovative treatments like pemvidutide. The dual GLP-1/glucagon mechanism of pemvidutide is positioned to deliver significant therapeutic benefits, including rapid resolution of MASH and improvements in liver health metrics, emphasizing its competitive edge in the pipeline of metabolic disease therapies. Additionally, strategic leadership enhancements within the company and the alignment of their clinical data with market trends bolster confidence in pemvidutide's ability to succeed during pivotal upcoming clinical milestones.

Bears say

Altimmune Inc faces several significant risks that contribute to a negative outlook on its stock. The clinical development of pemvidutide is burdened by uncertainties related to its efficacy and safety, along with intense competition in the biopharmaceutical sector, which could hinder commercialization efforts. Additionally, potential challenges in securing reimbursement, pricing pressures, and broader market risks, including capital dilution and disruptions from external events like the COVID-19 pandemic and geopolitical tensions, further compound the outlook for the company.

Altimmune (ALT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 6 analysts, Altimmune (ALT) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.